Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,157Revenue $M516Net Margin (%)--Altman Z-Score--
Enterprise Value $M9,157EPS $-1.6Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONXX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ONXXMario Gabelli 2013-09-30 Buy 0.47%$110.99 - $136.03
$ 124.70-2%New holding644,979
ONXXPrem Watsa 2013-09-30 Buy 0.04%$110.99 - $136.03
$ 124.70-2%New holding4,500
ONXXMariko Gordon 2013-09-30 Sold Out -0.03%$110.99 - $136.03
$ 124.70-2%Sold Out0
ONXXMariko Gordon 2013-06-30 Add0.01%$81.76 - $100.37
$ 124.7035%Add 72.04%7,138
ONXXVanguard Health Care Fund 2012-09-30 Reduce-0.1%$64.73 - $85.82
$ 124.7069%Reduce 24.40%1,022,700
ONXXGeorge Soros 2011-06-30 Sold Out $33.565 - $45.37
$ 124.70230%Sold Out0
ONXXGeorge Soros 2011-03-31 Add0.06%$34.05 - $37.67
$ 124.70248%Add 1576.09%154,200
ONXXGeorge Soros 2010-12-31 Reduce$25.53 - $37.1
$ 124.70313%Reduce 48.60%9,200
ONXXGeorge Soros 2010-09-30 Buy 0.01%$19.9 - $28.11
$ 124.70399%New holding17,900
ONXXVanguard Health Care Fund 2010-06-30 Add0.06%$21.7 - $31.18
$ 124.70384%Add 61.03%1,299,865
ONXXGeorge Soros 2010-03-31 Sold Out $27.76 - $32.46
$ 124.70314%Sold Out0
ONXXGeorge Soros 2009-12-31 Buy $25.13 - $30.04
$ 124.70346%New holding11,400
ONXXVanguard Health Care Fund 2009-09-30 Add0.03%$27.23 - $36.55
$ 124.70293%Add 32.94%807,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONXX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

ONXX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Torley HelenEVP, Chief Commercial Officer 2013-08-12Sell9,311$126.89-1.73 view
Fust Matthew KEVP & CFO 2013-08-08Sell2,492$128.21-2.74 view
SHEMA SUZANNE MEVP, GC and Corp. Secretary 2013-08-07Sell4,052$131.86-5.43 view
Foster-Cheek Kaye ISVP, Global Human Resources 2013-08-06Sell8,878$132.81-6.11 view
GRILLO LOPEZ ANTONIO JDirector 2013-07-30Sell1,500$131.26-5 view
Nevinny Corinne HDirector 2013-07-30Sell1,500$131.26-5 view
GRILLO LOPEZ ANTONIO JDirector 2013-07-26Sell2,000$130.5-4.44 view
Fust Matthew KEVP & CFO 2013-07-26Sell6,043$130.5-4.44 view
SHEMA SUZANNE MEVP, GC and Corp. Secretary 2013-07-08Sell4,052$135.76-8.15 view
Fust Matthew KEVP & CFO 2013-07-02Sell1,551$132.8-6.1 view

Quarterly/Annual Reports about ONXX:

    News about ONXX:

    Articles On GuruFocus.com
    Amgen Inc.’s First Quarter Earnings Preview – What Could Be In Store? Apr 20 2015 
    Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
    Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
    Mario Gabelli Comments on Onyx Pharmaceuticals Inc. Jan 03 2014 
    Columbia Wanger’s Third Quarter Selling Nov 20 2013 
    6 New Stock Picks from Prem Watsa Nov 19 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    ONYX Pharmaceuticals Inc. (ONXX) EVP & COO Laura Brege sells 12,500 Shares Jan 20 2011 
    ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 1,812 Shares Jan 07 2011 
    ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles sells 13,669 Shares Dec 08 2010 

    More From Other Websites
    Near the end, Onyx delivers once more with cancer-fighting drug Jul 24 2015
    On the move: New hires and appointments in the local life sciences industry May 11 2015
    Former Teva CEO's new gig at Ovid Therapeutics Apr 16 2015
    Could Amgen layoffs in California bring more biotech workers to Washington state? Mar 11 2015
    Amgen to lay off 300 at Onyx, close South S.F. facility Mar 10 2015
    Amgen Announces New Data from Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study in Patients... Dec 07 2014
    Amgen and Onyx Announce Detailed Results from Phase 3 ASPIRE Study of Kyprolis® (carfilzomib) in... Dec 06 2014
    Amgen Highlights New Data in The Treatment of Blood Cancers at ASH 2014 Nov 06 2014
    AstraZeneca buys US cancer drugs firm Aug 27 2013
    US biotech giant Amgen to buy rival Onyx for $10.4 bln Aug 25 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)